# NextConsensus > NextConsensus estimates the probability that guideline bodies, regulators, and payers will act on changing medical evidence before your review deadline. NextConsensus provides dated evidence histories and registered forecasts for defined guideline, label, and coverage decisions. Each entry below is a page's own title and description, listed in the order of the sitemap. Full page text: https://nextconsensus.com/llms-full.txt ## Registered forecasts - [Registered forecasts](https://nextconsensus.com/forecast/): Probabilities for FDA approvals by PDUFA date, NICE guidance by scheduled date, and NCCN listings, registered before the outcome under a rule that settles each. - [PDUFA calendar 2026–2027: FDA goal dates with registered forecasts](https://nextconsensus.com/pdufa-calendar/): FDA PDUFA goal dates for 27 applications, by month: the drug, the applicant, the review center, and a probability of approval registered before each date. - [NICE appraisal calendar 2026–2027: expected dates with registered forecasts](https://nextconsensus.com/nice-appraisal-calendar/): Expected NICE publication dates for 23 technology appraisals, by month: NICE's title, project ID and committee, and a probability registered before each date. - [75% forecast: NCCN lists sunvozertinib as a first-line option in EGFR exon 20 insertion NSCLC](https://nextconsensus.com/forecast/ff-001/): Registered 2026-08-17, before the outcome was known, at 75%, against a base rate of 62%. The rule that settles it is public; event by 2027-07-31. - [88% forecast: FDA approves a first-line indication for sunvozertinib in EGFR exon 20 insertion NSCLC](https://nextconsensus.com/forecast/ff-002/): Registered 2026-09-22, before the outcome was known, at 88%, against a base rate of 85%. The rule that settles it is public; event by 2027-07-31. - [55% forecast: FDA approves first-line sunvozertinib in EGFR exon 20 insertion NSCLC on or before 2027-03-31](https://nextconsensus.com/forecast/ff-003/): Registered 2026-09-22, before the outcome was known, at 55%, against a base rate of 60%. The rule that settles it is public; event by 2027-03-31. - [45% forecast: FDA first-line approval of sunvozertinib precedes the NCCN first-line listing](https://nextconsensus.com/forecast/ff-004/): Registered 2026-09-22, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2027-07-31. - [82% forecast: FDA approves the aficamten MAPLE-HCM supplement to NDA 219083 on or before the disclosed PDUFA goal date of 2026-11-14](https://nextconsensus.com/forecast/ff-005/): Registered 2026-09-26, before the outcome was known, at 82%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-14. - [85% forecast: FDA approves BBP-418 for limb-girdle muscular dystrophy type 2I/R9 on or before the disclosed PDUFA goal date of 2026-11-27](https://nextconsensus.com/forecast/ff-006/): Registered 2026-09-26, before the outcome was known, at 85%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-27. - [84% forecast: FDA approves bepirovirsen for chronic hepatitis B on or before the disclosed PDUFA goal date of 2026-10-26](https://nextconsensus.com/forecast/ff-007/): Registered 2026-09-26, before the outcome was known, at 84%, against a base rate of 85%. The rule that settles it is public; event by 2026-10-26. - [35% forecast: FDA approves deramiocel for Duchenne muscular dystrophy on or before the disclosed PDUFA goal date of 2026-11-22](https://nextconsensus.com/forecast/ff-008/): Registered 2026-09-26, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-22. - [35% forecast: FDA approves the IGALMI at-home use supplement to NDA 215390 on or before the disclosed PDUFA goal date of 2026-11-14](https://nextconsensus.com/forecast/ff-009/): Registered 2026-09-26, before the outcome was known, at 35%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-14. - [45% forecast: FDA approves INO-3107 for recurrent respiratory papillomatosis on or before the disclosed PDUFA goal date of 2026-10-30](https://nextconsensus.com/forecast/ff-010/): Registered 2026-09-26, before the outcome was known, at 45%, against a base rate of 70%. The rule that settles it is public; event by 2026-10-30. - [15% forecast: FDA approves ivonescimab for EGFR-mutated non-small cell lung cancer after EGFR TKI therapy on or before the disclosed PDUFA goal date of 2026-11-14](https://nextconsensus.com/forecast/ff-011/): Registered 2026-09-26, before the outcome was known, at 15%, against a base rate of 70%. The rule that settles it is public; event by 2026-11-14. - [72% forecast: FDA approves the mitapivat sickle cell disease supplement to NDA 216196 on or before the disclosed PDUFA goal date of 2026-11-01](https://nextconsensus.com/forecast/ff-012/): Registered 2026-09-26, before the outcome was known, at 72%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-01. - [75% forecast: FDA approves molgramostim (MOLBREEVI) for autoimmune pulmonary alveolar proteinosis on or before the disclosed PDUFA goal date of 2026-11-22](https://nextconsensus.com/forecast/ff-013/): Registered 2026-09-26, before the outcome was known, at 75%, against a base rate of 80%. The rule that settles it is public; event by 2026-11-22. - [35% forecast: NICE publishes technology appraisal guidance on Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] on or before 2026-11-18](https://nextconsensus.com/forecast/ff-014/): Registered 2026-09-26, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-18. - [45% forecast: NICE publishes technology appraisal guidance on Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409] on or before 2026-11-18](https://nextconsensus.com/forecast/ff-015/): Registered 2026-09-26, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-18. - [45% forecast: NICE publishes technology appraisal guidance on Epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6586] on or before 2026-10-28](https://nextconsensus.com/forecast/ff-016/): Registered 2026-09-26, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2026-10-28. - [50% forecast: NICE publishes technology appraisal guidance on Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425] on or before 2026-11-03](https://nextconsensus.com/forecast/ff-017/): Registered 2026-09-26, before the outcome was known, at 50%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-03. - [55% forecast: NICE publishes technology appraisal guidance on Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292] on or before 2026-11-18](https://nextconsensus.com/forecast/ff-018/): Registered 2026-09-26, before the outcome was known, at 55%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-18. - [45% forecast: NICE publishes technology appraisal guidance on Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239] on or before 2026-11-11](https://nextconsensus.com/forecast/ff-019/): Registered 2026-09-26, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-11. - [5% forecast: NICE publishes technology appraisal guidance on Orforglipron for managing overweight and obesity [ID6516] on or before 2026-11-18](https://nextconsensus.com/forecast/ff-020/): Registered 2026-09-26, before the outcome was known, at 5%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-18. - [50% forecast: NICE publishes technology appraisal guidance on Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363] on or before 2026-11-18](https://nextconsensus.com/forecast/ff-021/): Registered 2026-09-26, before the outcome was known, at 50%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-18. - [50% forecast: NICE publishes technology appraisal guidance on Zuranolone for treating postnatal depression [ID6431] on or before 2026-11-12](https://nextconsensus.com/forecast/ff-022/): Registered 2026-09-26, before the outcome was known, at 50%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-12. - [85% forecast: FDA approves bezuclastinib with sunitinib for gastrointestinal stromal tumor after imatinib on or before the disclosed PDUFA goal date of 2026-11-30](https://nextconsensus.com/forecast/ff-023/): Registered 2026-10-06, before the outcome was known, at 85%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-30. - [55% forecast: FDA approves D-PLEX100 (extended-release doxycycline) for prevention of surgical site infections in colorectal surgery on or before the disclosed PDUFA goal date of 2026-11-28](https://nextconsensus.com/forecast/ff-024/): Registered 2026-10-06, before the outcome was known, at 55%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-28. - [85% forecast: FDA approves neladalkib for ALK-positive non-small cell lung cancer after a prior ALK inhibitor on or before the disclosed PDUFA goal date of 2026-11-27](https://nextconsensus.com/forecast/ff-025/): Registered 2026-10-06, before the outcome was known, at 85%, against a base rate of 70%. The rule that settles it is public; event by 2026-11-27. - [85% forecast: FDA approves povetacicept for IgA nephropathy on or before the disclosed PDUFA goal date of 2026-11-30](https://nextconsensus.com/forecast/ff-026/): Registered 2026-10-06, before the outcome was known, at 85%, against a base rate of 70%. The rule that settles it is public; event by 2026-11-30. - [75% forecast: FDA approves venglustat for type 3 Gaucher disease on or before the disclosed PDUFA goal date of 2026-11-25](https://nextconsensus.com/forecast/ff-027/): Registered 2026-10-06, before the outcome was known, at 75%, against a base rate of 85%. The rule that settles it is public; event by 2026-11-25. - [40% forecast: NICE publishes technology appraisal guidance on Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID6519] on or before 2026-11-25](https://nextconsensus.com/forecast/ff-028/): Registered 2026-10-06, before the outcome was known, at 40%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-25. - [35% forecast: NICE publishes technology appraisal guidance on Polihexanide 0.8 mg/ml eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] on or before 2026-11-25](https://nextconsensus.com/forecast/ff-029/): Registered 2026-10-06, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-25. - [75% forecast: FDA approves anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma after 3 or more lines on or before the disclosed PDUFA goal date of 2026-12-23](https://nextconsensus.com/forecast/ff-030/): Registered 2026-10-15, before the outcome was known, at 75%, against a base rate of 70%. The rule that settles it is public; event by 2026-12-23. - [80% forecast: FDA approves bezuclastinib for nonadvanced systemic mastocytosis on or before the disclosed PDUFA goal date of 2026-12-30](https://nextconsensus.com/forecast/ff-031/): Registered 2026-10-15, before the outcome was known, at 80%, against a base rate of 85%. The rule that settles it is public; event by 2026-12-30. - [70% forecast: FDA approves imsidolimab for generalized pustular psoriasis on or before the disclosed PDUFA goal date of 2026-12-12](https://nextconsensus.com/forecast/ff-032/): Registered 2026-10-15, before the outcome was known, at 70%, against a base rate of 85%. The rule that settles it is public; event by 2026-12-12. - [82% forecast: FDA approves lorundrostat for hypertension on or before the disclosed PDUFA goal date of 2026-12-22](https://nextconsensus.com/forecast/ff-033/): Registered 2026-10-15, before the outcome was known, at 82%, against a base rate of 85%. The rule that settles it is public; event by 2026-12-22. - [45% forecast: FDA approves relacorilant for Cushing's syndrome (resubmission) on or before the disclosed PDUFA goal date of 2026-12-17](https://nextconsensus.com/forecast/ff-034/): Registered 2026-10-15, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2026-12-17. - [80% forecast: FDA approves relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies on or before the disclosed PDUFA goal date of 2026-12-27](https://nextconsensus.com/forecast/ff-035/): Registered 2026-10-15, before the outcome was known, at 80%, against a base rate of 85%. The rule that settles it is public; event by 2026-12-27. - [80% forecast: FDA approves ulixacaltamide for essential tremor on or before the disclosed PDUFA goal date of 2027-01-29](https://nextconsensus.com/forecast/ff-036/): Registered 2026-10-15, before the outcome was known, at 80%, against a base rate of 85%. The rule that settles it is public; event by 2027-01-29. - [70% forecast: FDA approves zeleciment rostudirsen (z-rostudirsen) for Duchenne muscular dystrophy amenable to exon 51 skipping on or before the disclosed PDUFA goal date of 2027-01-21](https://nextconsensus.com/forecast/ff-037/): Registered 2026-10-15, before the outcome was known, at 70%, against a base rate of 70%. The rule that settles it is public; event by 2027-01-21. - [30% forecast: NICE publishes technology appraisal guidance on Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653] on or before 2027-01-28](https://nextconsensus.com/forecast/ff-038/): Registered 2026-10-15, before the outcome was known, at 30%, against a base rate of 50%. The rule that settles it is public; event by 2027-01-28. - [40% forecast: NICE publishes technology appraisal guidance on Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis [ID6446] on or before 2027-01-20](https://nextconsensus.com/forecast/ff-039/): Registered 2026-10-15, before the outcome was known, at 40%, against a base rate of 50%. The rule that settles it is public; event by 2027-01-20. - [30% forecast: NICE publishes technology appraisal guidance on Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482] on or before 2026-12-16](https://nextconsensus.com/forecast/ff-040/): Registered 2026-10-15, before the outcome was known, at 30%, against a base rate of 50%. The rule that settles it is public; event by 2026-12-16. - [30% forecast: NICE publishes technology appraisal guidance on Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617] on or before 2027-01-13](https://nextconsensus.com/forecast/ff-041/): Registered 2026-10-15, before the outcome was known, at 30%, against a base rate of 50%. The rule that settles it is public; event by 2027-01-13. - [40% forecast: NICE publishes technology appraisal guidance on Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406] on or before 2027-01-13](https://nextconsensus.com/forecast/ff-042/): Registered 2026-10-15, before the outcome was known, at 40%, against a base rate of 50%. The rule that settles it is public; event by 2027-01-13. - [30% forecast: NICE publishes technology appraisal guidance on Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680] on or before 2027-01-27](https://nextconsensus.com/forecast/ff-043/): Registered 2026-10-15, before the outcome was known, at 30%, against a base rate of 50%. The rule that settles it is public; event by 2027-01-27. - [80% forecast: FDA approves oral infigratinib for children with achondroplasia on or before the disclosed PDUFA goal date of 2027-02-04](https://nextconsensus.com/forecast/ff-044/): Registered 2026-10-15, before the outcome was known, at 80%, against a base rate of 85%. The rule that settles it is public; event by 2027-02-04. - [70% forecast: FDA approves once-weekly oral lenacapavir (YEZTUGO) for HIV-1 pre-exposure prophylaxis on or before the disclosed PDUFA goal date of 2027-02-02](https://nextconsensus.com/forecast/ff-045/): Registered 2026-10-15, before the outcome was known, at 70%, against a base rate of 85%. The rule that settles it is public; event by 2027-02-02. - [85% forecast: FDA approves the leniolisib (JOENJA) pediatric supplement for APDS in children weighing 13 kg to 27 kg on or before the disclosed PDUFA goal date of 2027-01-30](https://nextconsensus.com/forecast/ff-046/): Registered 2026-10-15, before the outcome was known, at 85%, against a base rate of 85%. The rule that settles it is public; event by 2027-01-30. - [78% forecast: FDA approves fast-acting meloxicam (MR-107A-02) for moderate-to-severe acute pain on or before the disclosed PDUFA goal date of 2026-12-27](https://nextconsensus.com/forecast/ff-047/): Registered 2026-10-15, before the outcome was known, at 78%, against a base rate of 85%. The rule that settles it is public; event by 2026-12-27. - [35% forecast: NICE publishes technology appraisal guidance on Intrathecal onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556] on or before 2026-11-25](https://nextconsensus.com/forecast/ff-048/): Registered 2026-10-15, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2026-11-25. - [35% forecast: NICE publishes technology appraisal guidance on Pembrolizumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6607] on or before 2027-02-10](https://nextconsensus.com/forecast/ff-049/): Registered 2026-10-15, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2027-02-10. - [35% forecast: NICE publishes technology appraisal guidance on Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529] on or before 2026-12-09](https://nextconsensus.com/forecast/ff-050/): Registered 2026-10-15, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2026-12-09. - [25% forecast: NICE publishes technology appraisal guidance on Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458] on or before 2027-01-07](https://nextconsensus.com/forecast/ff-051/): Registered 2026-10-15, before the outcome was known, at 25%, against a base rate of 50%. The rule that settles it is public; event by 2027-01-07. - [45% forecast: NICE publishes technology appraisal guidance on Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113] on or before 2027-02-10](https://nextconsensus.com/forecast/ff-052/): Registered 2026-10-15, before the outcome was known, at 45%, against a base rate of 50%. The rule that settles it is public; event by 2027-02-10. - [70% forecast: FDA approves oral tinlarebant for Stargardt disease type 1 on or before the disclosed PDUFA goal date of 2027-02-12](https://nextconsensus.com/forecast/ff-053/): Registered 2026-10-21, before the outcome was known, at 70%, against a base rate of 80%. The rule that settles it is public; event by 2027-02-12. - [35% forecast: NICE publishes technology appraisal guidance on Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609] on or before 2027-02-17](https://nextconsensus.com/forecast/ff-054/): Registered 2026-10-21, before the outcome was known, at 35%, against a base rate of 50%. The rule that settles it is public; event by 2027-02-17. ## Evidence ledgers - [Evidence Ledgers](https://nextconsensus.com/ledger/): Evidence ledgers: dated, sourced, hash-chained records of what institutions put on the record about an asset, with no probabilities. - [Evidence ledger: Sunvozertinib, first line, EGFR exon 20 insertion NSCLC](https://nextconsensus.com/ledger/sunvozertinib-first-line/): Evidence ledger for Sunvozertinib, first line, EGFR exon 20 insertion NSCLC: 8 dated, sourced, hash-chained rows from 2026-05-27 to 2026-08-17. ## For teams - [Who It's For](https://nextconsensus.com/use-cases/): What market access, HEOR, and BD teams ask before a coverage review, an HTA submission, or a transaction, and what is possible at each distance from the date. - [Start with one claim](https://nextconsensus.com/contact/): Name the claim you are taking into a review, or the guideline, label, or coverage decision you are waiting on, and the date. - [Programs](https://nextconsensus.com/programs/): One claim, $9,500, ten business days: its dated evidence and a registered probability that the guideline body, regulator, or payer acts by your review date. ## Guides - [Guideline, Approval, and Coverage Planning Guides](https://nextconsensus.com/guides/): Prepare for guideline, label, and coverage changes: FDA goal dates, oncology sequencing, evidence deadlines, GLP-1 policies, and CMS and NICE windows. - [Taking a claim into a coverage or P&T review](https://nextconsensus.com/guides/coverage-review/): Taking a claim into a coverage reconsideration or P&T review: rerun the restriction's PICO against today's record and bring the dated three-item packet. - [Guideline or label changes before your date](https://nextconsensus.com/guides/guideline-windows/): Guidelines, labels, and coverage policies keep moving after a claim is written. This guide shows where, with seven questions to check before your date. - [The 12-Rung Evidence-to-Action Ladder](https://nextconsensus.com/guides/evidence-to-action-ladder/): The 12-rung ladder is a public vocabulary for describing how medical change moves from evidence through institutional action to its consequences. - [FDA approval, NCCN guidelines, and payer coverage: three separate decisions](https://nextconsensus.com/guides/approval-guideline-coverage/): How oncology market access teams distinguish label approval, guideline inclusion, and payer coverage, and prepare when their dates diverge. - [Label expansion readiness: planning for a new indication](https://nextconsensus.com/guides/label-expansion-readiness/): A preparation guide for regulatory, launch, and market access teams assessing a possible label expansion and an earlier or later decision date. - [Evidence preparation before a P&T or HTA deadline](https://nextconsensus.com/guides/evidence-preparation/): What market access, HEOR, and medical affairs teams can prepare twelve, six, or three months before a committee or submission deadline. - [When a guideline, label, or coverage change is delayed](https://nextconsensus.com/guides/delayed-transitions/): Distinguish missing evidence, procedural delay, a different action, and an outcome after the deadline when an institutional change does not arrive. - [GLP-1 coverage changes: start with the indication and the plan](https://nextconsensus.com/guides/glp1-coverage-by-indication/): A guide for market access and payer teams comparing GLP-1 coverage by indication, population, benefit, and effective date, with historical evidence examples. - [CMS and NICE timelines: decision dates and implementation windows](https://nextconsensus.com/guides/authority-decision-windows/): Distinguish CMS national coverage review milestones from NICE technology appraisal funding windows when planning evidence and implementation work. - [What is a PDUFA date? Plan for approval, a CRL, or an extension](https://nextconsensus.com/guides/pdufa-goal-dates/): A PDUFA date is FDA's target for acting on a drug or biologic application. What approval, a CRL, an extension or a missed date means for a launch or deal plan. - [NICE scheduled dates: plan for publication, a delay, or a suspension](https://nextconsensus.com/guides/nice-scheduled-dates/): What an expected NICE publication date commits NICE to, which outcomes a UK launch or access plan must cover, and where NICE's own record confirms the action. ## Examples and historical reconstructions - [Semaglutide: from high-risk comorbidity settings to general obesity weight management](https://nextconsensus.com/baselines/semaglutide/): Review of a metabolic claim that began in a high-risk comorbidity setting and is now being extended to general adult obesity weight management. - [GLP-1 receptor agonist (public encyclopedia provenance reconstruction)](https://nextconsensus.com/baselines/provenance/glp1/): Provenance reconstruction of GLP-1 receptor agonist from a public encyclopedia revision history: 22 sources and 9 dated events, 2005 to 2024. - [Liraglutide (public encyclopedia provenance reconstruction)](https://nextconsensus.com/baselines/provenance/liraglutide/): Provenance reconstruction of Liraglutide from a public encyclopedia revision history: 20 sources and 3 dated events, 2010 to 2024. - [Examples](https://nextconsensus.com/examples/): One of each thing NextConsensus delivers: an evidence ledger, a registered forecast, and reconstructions from the historical record. - [Reconstructions](https://nextconsensus.com/case-library/): How a claim moved through the public record, reconstructed and cut off at its evidence date, for assets a market access or regulatory team knows. - [Evidence Change Feed](https://nextconsensus.com/evidence-change/): Dated, sourced acts by guideline bodies, regulators, and payers on the assets NextConsensus keeps a record for. Nothing here is a forecast. - [Sunvozertinib First-Line NSCLC: FDA, NCCN, and Decision Timing](https://nextconsensus.com/baselines/sunvozertinib-first-line/): A sourced dossier on first-line sunvozertinib in EGFR exon 20 insertion NSCLC: the evidence, registered FDA and NCCN questions, and preparation if dates move. ## Method - [Research](https://nextconsensus.com/research/): The research program: whether guideline, regulatory, and payer actions can be forecast from public evidence, and whether the probabilities are calibrated. - [How It Works](https://nextconsensus.com/how-it-works/): How we reconstruct the evidence behind a claim, date each guideline, label, and coverage change, and register a decision's probability before your deadline. - [Method](https://nextconsensus.com/method/): How a forecast is specified, frozen at an evidence cutoff, read against its registered rule in two readings that must agree, scored, and declined when the record will not carry one. - [Verify a record](https://nextconsensus.com/verification/): Recompute the specification hash of a published forecast from its canonical fields. ## Company - [About](https://nextconsensus.com/about/): NextConsensus provides dated evidence histories and registered forecasts for defined guideline, label, and coverage decisions. - [Security & Compliance](https://nextconsensus.com/security/): Everything NextConsensus uses is public; what you tell us about your decision stays private. How inquiries, programs and the public record handle data. - [Legal](https://nextconsensus.com/legal/): What these pages and records may be used for (not medical, legal, or investment advice), how this site handles your data, and how to request program agreements.